FDA's Gottlieb: 'Pricing And Reimbursement Mischief' Holding Back Biosimilar Market
The FDA Commissioner called on payers to take steps to build the US biosimilar market and discouraged some early contracting schemes, calling them pay-for-delay tactics "dressed in the guise of rebates" in a notable speech at AHIP.
You may also be interested in...
United HealthCare agreed to cover Mvasi and Kanjinti in a preferred position. Amgen VP-oncology sales & marketing Susan Logan talked to Scrip about the company's first US biosimilar launches.
Without constraints of being FDA commissioner, Gottlieb will have podium to push for changes to drug pricing and competition.
A look back at the Scrip stories that piqued the most interest for our readers in 2018.